A new study published in Alzheimer’s Research & Therapy has examined how plasma phosphorylated tau 217 (p-tau217) performs in routine clinical practice and how its introduction is influencing the diagnostic evaluation of cognitive disorders.
The researchers analysed data from 1,368 patients who underwent plasma p-tau217 testing between January and December 2025 across 24 clinical centres in Belgium. Among patients with a clinical suspicion of Alzheimer’s disease, 66.1% had positive p-tau217 results, compared with 17.8% of those suspected of having non-Alzheimer’s cognitive disorders. Patients without a specific diagnostic hypothesis showed an intermediate distribution, with 34.6% positive results. The researchers also found that p-tau217 concentrations were associated with age, sex and kidney function, highlighting the importance of considering these factors when interpreting biomarker results.
In a subset of 117 patients with available cerebrospinal fluid (CSF) biomarker data, plasma p-tau217 showed a strong correlation with the CSF p-tau181/Aβ42 ratio. The study also explored how the introduction of plasma p-tau217 influenced diagnostic practice. Among 53 clinicians surveyed, 71% reported increased confidence in the biomarker. Moreover, 80% reported shorter diagnostic delays and 63% reported reduced use of brain FDG-PET. These findings were supported by clinical activity data, which showed that CSF biomarker requests across participating centres decreased by approximately 46% between early 2024 and late 2025.
The authors conclude that plasma p-tau217 could play an increasingly important role in the diagnostic work-up of cognitive disorders, helping to reduce the use of invasive procedures and streamline diagnostic pathways. However, they emphasise that results should be interpreted alongside the clinical context and patient-specific factors, particularly age and renal function and that blood-based biomarkers complement rather than replace established diagnostic investigations.
Link to article: https://link.springer.com/article/10.1186/s13195-026-02244-9#Sec20